Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
950130.KQ
STRONG SELLAccess Bio, Inc. · Healthcare · United States · $60M · Avg Vol: $90K/d
8
StockRankGet insider-trade alerts
Q
32
V
38
M
14
P/E (TTM)
—
ROE
-13.8%
D/E
0.1x
Dividend %
—
COMPANY DESCRIPTION
Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, immunochemical diagnostics, biosensors, and molecular diagnostic products worldwide.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 673.5M | 227.1M | 73.3M | 20.4M | -68.8% | 9.7M |
| EPS | 6.55 | -0.06 | -0.01 | -1.52 | — | -1.52 |
| Shares | 34.0M | 33.8M | 35.2M | 35.2M | +3.6% | 35.2M |
| Debt | 49.1M | 47.6M | 43.0M | 27.9M | -17.2% | 28.5M |
| Equity | 402.7M | 380.6M | 423.6M | 363.0M | -3.4% | — |
| Op CF | 240.5M | -67.7M | 13.0M | -19.0M | -76.8% | -46.0M |
| Inv CF | -24.6M | -30.3M | 11.4M | 14.2M | — | — |
| Fin CF | -43.9M | -35.2M | -4.9M | -3.2M | — | — |
Loading 1Y...
PRICE (1Y)-11.7%
SMA 50SMA 200
Close
$1.47
RSI (14)
51.3
52W High
$3.63
From 52W High
0.4%
SCORE BREAKDOWN
Quality
32
ROIC
-17.7%29.4
ROE
-13.8%33.0
GP/Assets
-5.5%7.3
Op. Margin
-209.6%13.4
FCF/Assets
-5.7%32.5
Piotroski
430.5
Int. Cover
-44.4x12.7
D/E Ratio
0.08x67.0
Current Ratio
16.86x93.7
Value
38
P/E (TTM)
—N/A
EV/EBITDA
4.8x25.0
P/FCF
—N/A
P/B
0.1x100.0
P/S
5.4x39.5
Div Yield
—N/A
Momentum
14
52W High %
40%15.3
RS 6M
-79%4.8
SMA 50/200
0.79x17.5
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$60M
P/E (Forward)
—
Gross Margin
-225.4%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 950130.KQ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 950130.KQ | Access Bio, Inc.(you) | $60M | 8 | STRONG SELL |
| BDSX | Biodesix, Inc. | $228M | 38 | HOLD |
| CSTL | Castle Biosciences, Inc. | $749M | 18 | STRONG SELL |
| FLGT | Fulgent Genetics, Inc. | $559M | 27 | SELL |
| MYGN | Myriad Genetics, Inc. | $530M | 36 | HOLD |
| WGS | GeneDx Holdings Corp. | $1.8B | 13 | STRONG SELL |
| OPK | OPKO Health, Inc. | $921M | 31 | SELL |
| GRAL | GRAIL, Inc. | $2.9B | 19 | STRONG SELL |
| KALA | KALA BIO, Inc. | $63M | 9 | STRONG SELL |
| CNTX | Context Therapeutics Inc. | $56M | 10 | STRONG SELL |
Peer medians: ROE -21.2% · P/E 27.9x · Gross margin 50.0%